{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CLAG-M",
    "query": {
      "intervention": "CLAG-M"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CLAG-M&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T11:05:37.171Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01513603",
      "title": "Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Lymphoblastic Lymphoma",
        "Burkitts Leukemia/Lymphoma",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "CLAG-M",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 50,
      "start_date": "2012-01",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2012-01-20",
      "last_synced_at": "2026-09-15T11:05:37.171Z",
      "location_count": 1,
      "location_summary": "Valhalla, New York",
      "locations": [
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01513603"
    },
    {
      "nct_id": "NCT03441048",
      "title": "Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Lintuzumab-Ac-225",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2018-05-22",
      "completion_date": "2024-05-22",
      "has_results": false,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-09-15T11:05:37.171Z",
      "location_count": 1,
      "location_summary": "Milwuakee, Wisconsin",
      "locations": [
        {
          "city": "Milwuakee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03441048"
    },
    {
      "nct_id": "NCT03257241",
      "title": "A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "A arm (DA-90)",
          "type": "DRUG"
        },
        {
          "name": "B arm (DAC)",
          "type": "DRUG"
        },
        {
          "name": "A arm (CLAG-M)",
          "type": "DRUG"
        },
        {
          "name": "B arm (FLAG-IDA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Polish Adult Leukemia Group",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 582,
      "start_date": "2017-07-03",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-10-01",
      "last_synced_at": "2026-09-15T11:05:37.171Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03257241"
    },
    {
      "nct_id": "NCT03926624",
      "title": "Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "DFP-10917",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Cladribine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Delta-Fly Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 167,
      "start_date": "2019-11-22",
      "completion_date": "2026-01-07",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-09-15T11:05:37.171Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03926624"
    },
    {
      "nct_id": "NCT06660368",
      "title": "BCL2i CLAG-M in R/R Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed or Refractory Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 52,
      "start_date": "2024-11-26",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-09-15T11:05:37.171Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Boston, Massachusetts",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06660368"
    },
    {
      "nct_id": "NCT06007911",
      "title": "Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Adult AML",
        "Refractory AML"
      ],
      "interventions": [
        {
          "name": "Navitoclax Dose Level 1",
          "type": "DRUG"
        },
        {
          "name": "Navitoclax Dose Level 0",
          "type": "DRUG"
        },
        {
          "name": "Navitoclax Dose Level 2",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax Dose Level -1",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax Dose Levels 0 to 2",
          "type": "DRUG"
        },
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (Cladribine Low Dose Cytarabine Backbone)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (CLAG-M Backbone)",
          "type": "DRUG"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte Colony-Stimulating Factor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-08-31",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2024-08-13",
      "last_synced_at": "2026-09-15T11:05:37.171Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06007911"
    },
    {
      "nct_id": "NCT04375631",
      "title": "CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Chronic Myelomonocytic Leukemia",
        "Recurrent Myelodysplastic Syndrome",
        "Refractory Acute Myeloid Leukemia",
        "Refractory Chronic Myelomonocytic Leukemia",
        "Refractory Mixed Phenotype Acute Leukemia",
        "Refractory Myelodysplastic Syndrome",
        "Refractory Acute Leukemia of Ambiguous Lineage",
        "Refractory Acute Undifferentiated Leukemia"
      ],
      "interventions": [
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Sodium",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2020-12-03",
      "completion_date": "2027-03-17",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-09-15T11:05:37.171Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04375631"
    },
    {
      "nct_id": "NCT05330377",
      "title": "GM-CLAG in Relapsed/Refractory FLT3-mutated AML",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Gilteritinib 40 MG Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ayman H Qasrawi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-03",
      "completion_date": "2032-05-30",
      "has_results": false,
      "last_update_posted_date": "2023-04-25",
      "last_synced_at": "2026-09-15T11:05:37.171Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05330377"
    },
    {
      "nct_id": "NCT00955916",
      "title": "CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "CLAG Regimen",
          "type": "DRUG"
        },
        {
          "name": "Gleevec®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2009-08",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2014-06-27",
      "last_synced_at": "2026-09-15T11:05:37.171Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00955916"
    },
    {
      "nct_id": "NCT04195945",
      "title": "CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myeloid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Liposome-encapsulated Daunorubicin-Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Granulocyte Colony-Stimulating Factor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2020-05-27",
      "completion_date": "2026-05-20",
      "has_results": true,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-09-15T11:05:37.171Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04195945"
    }
  ]
}